News Hub | News Direct

The Highly Anticipated NILU Hypercar has Arrived!

Nilu

Nilu27, the hypercar brand recently founded by celebrated sports car designer Sasha Selipanov, is thrilled to showcase its first vehicle: the self-titled NILU hypercar. Following a number of social media teasers, which created a stir among the sports car community, the car can finally be revealed in its entirety. The NILU hypercar challenges traditional automotive industry trends. By avoiding electrification, digitalization, and other technological aids, NILU will deliver a raw, unfiltered, uncensored driving experience. Taking inspiration from sources such as ’60s F1 and Le Mans racers, classic Italian design houses, the Bauhaus “form follows function” philosophy, old school American muscle, drift cars, mathematics, and avant garde metal music, NILU’s no-nonsense design is as eclectic as it is original. Sasha’s goal was to create a car with an “inevitable” design: fresh and yet somehow familiar. The resulting NILU exterior, with its tight cross sections and sinuous curves, is functional, lean and aerodynamic. For maximum contrast, it juxtaposes clean sculptural surfaces with its mechanical, exposed and intricately detailed engine bay. True to Bauhaus philosophy, NILU eschews superfluous styling features to celebrate essential functional beauty. The NILU chassis features a bespoke carbon fiber monocoque with lightweight aluminum-alloy tubular subframes. In contrast to “fashionable” composite subframes, the designer deliberately chose a tubular approach to improve access to the drivetrain components while effortlessly facilitating heat extraction and celebrating the mechanical aesthetic. The NILU cabin was designed to provide perfect viewing angles with ideal ergonomics and safety. The designer was able to achieve an incredibly low roofline and compact cabin dimensions without sacrificing comfort. NILU seats two adults in a traditional side-by-side layout with best-in-class ingress and egress made possible by substantial gullwing doors, low sill heights, and fixed, sunken seats, which do not obstruct the door apertures with their side bolsters. The NILU human/machine interface is all about manual, analog controls, inputs and feedback. The only screen is the rear view camera/mirror, which addresses the traditional weakness of mid-engined sports cars: the lack of rearward visibility. The steering wheel’s compact size and perfectly round shape allows for incredibly detailed steering feel and input precision. The wheel is void of switches, buttons and toggles; a testament to the belief that performance driving requires full concentration with zero distractions. Gone are the driving modes, settings and options: NILU controls are both primary and intuitive. For this reason, an open-gate, seven-speed manual transmission celebrates raw, analog driving while adding a safety element with its reverse gear lock-out. Steering wheel, pedal box, headrest, door mirrors and other adjustments are deliberately manual, accessed by gratifying manual levers and switches. The tactile, haptic feedback from cold-touch, machined billet controls was deemed both more engaging and, crucially, safer than navigating through screen menus. PRODUCTION The NILU hypercar is Sasha’s vision in its purest form; a vision he’s been perfecting since 2006. It will initially be available in an extremely limited run with production capped at 15 units. “ My path in the industry has never been about following rules and sticking to norms,” Sasha explained. “I was never afraid to follow my intuition or chase my dreams. Breaking conventions is simply a byproduct. The same is true for NILU – a hypercar that discards current trends and conventions in pursuit of an elevated automotive experience. “Unveiling NILU to the world is a dream come true; a moment so profound it is hard to express in words. The vision was the result of a decades-long search, sleepless nights, years of overthinking and overanalyzing. I was fortunate to learn from and contribute to the industry’s best; now my team and I are thrilled to put all this vision and knowledge into action.” V12 ENGINE Nilu27 has partnered with Hartley Engines in New Zealand to produce one of the most powerful and visually striking naturally aspirated engines in the world. The NILU engine bay is fully exposed, showcasing the beautiful 6.5-liter, 80-degree V12. As NILU will not rely on electrification, it aims to be the world’s most powerful, naturally aspirated hypercar. To achieve this, the V12 will deliver more than 1000 horsepower. And while its large bore and short stroke will make it rev like an electric motor, the even-fire engine will provide the driver with the perfect amount of tactile vibration. The Hartley V12 has a refined combustion area, high-flow ports, and performance-style valve geometry: something OEMs typically cannot accommodate in their compact platforms. The engine also features 12 large, individual throttle bodies for instant throttle response. Another key differentiator for the NILU V12 is its unique “Hot V.” In this configuration, the conventional exhaust and intake positions are swapped around. The setup delivers key advantages when it comes to packaging, heat extraction, and aesthetics. And it has allowed the stunning “snakepit” 12-into-1 exhaust headers to serve as a unique highlight of the exterior design. The entire exhaust system was 3D-printed in Inconel, allowing the complex design to be realized; another unique feature when you consider its dimensions. Mated to the seven-speed CIMA manual transmission, and housed in the ceramic-coated aluminum-alloy subframe, the NILU V12 represents functional beauty at its finest. Nelson Hartley, founder and CEO of Hartley Engines, said, “We’ve been quietly working on the design and layout of our own engine for the last few years, taking inspiration from late ’80s and early ’90s Formula 1 cars. We strove for the kind of engineering that’s raw, endearing, emotional, and sometimes a little crazy. “With Sasha’s wishlist for NILU, we finally found the perfect project to dedicate our time and were able to adapt our development into his Hot V configuration, designing the engine around his chassis layout. “Make no mistake; this is not an OEM engine from another manufacturer converted to the Hot V; this is a bespoke, large bore, short stroke monster. It’s got aggressive cams, aggressive port flow, lightweight components and exotic materials. We want to get a cold sweat every time the V12 starts and revs. It’s fair to say, we’re very excited!" DYNAMICS The NILU hypercar employs a double wishbone, pushrod suspension, with its extremely long wishbones visible from the rear; the length contributing to the exceptionally precise and compliant handling characteristics. A set of Michelin Pilot Sport Cup 2 R tires were fitted, specified at 265/35 R20 front and 325/30 R21 rear. They have been mounted to 10x20” and 13x21” Nilu27 centerlock wheels, which were designed in-house with intricate lightweight detailing to reduce the unsprung weight. The wheels are produced by AppTech in Italy. Carbon-ceramic braking equipment was sourced from Brembo. The Italian company’s GT | BM calipers are fitted front and rear in a custom white finish. The car also has Brembo’s highest performance CCM-R Plus rotors, which deliver outstanding performance and fade resistance. THE FUTURE The initial NILU prototype vehicles and first batch of customer cars will be assembled by Aria Group in Irvine, CA, allowing Nilu27 to ramp-up its own facilities overseas. Nilu27 is simultaneously developing a street homologated version. This variant will be limited to 54 units, four of which will be unique, one-off designs. “We’ve been fascinated by the strong reaction to our social media teasers alone,” said Inna Selipanov, the company’s Co-Founder and COO. “While the world is moving towards electrification, and for very good reason, we firmly believe the timelessness of these cars will not only keep them relevant but they will continue to find a place in the collections of passionate car lovers.” Nilu27 is proud to have the support of industry leaders such as Aerotak, AppTech, Aria Group, Brembo, CIMA, Hartley Engines, Michelin, and Schroth. The car will be unveiled to a select VIP and media group at a private Los Angeles event on August 8. Its public debut will follow on August 15 on the ramp at Pebble Beach in Monterey, California, before appearing on the Concept Lawn at the Pebble Beach Concours d’Elegance on August 18. The NILU hypercar will also debut in CSR Racing 2; the hyper-real mobile racing game from Zynga’s NaturalMotion. Players can experience the high-octane performance and stunning in-game design this November. EDITOR’S NOTE Images for editorial use are available here: https://www.dropbox.com/scl/fo/slb7tdet19fb5pomdq8vo/AJPBTh72JpXxQSJDFwZA6JI?rlkey=4cn745k7vb2sxs4fmlfwwk5gb&dl=0 Please contact us if high-resolution images are required for print. A NILU video is available to view and share here: https://youtu.be/2gbQEQwedr8 ABOUT Nilu27 Founded in 2024 by Sasha and Inna Selipanov, Nilu27 is on a mission to produce quintessential sports cars that will withstand the test of time. With a primary focus on a visceral driving experience, the company’s purpose is to celebrate all elements of the car that engage the senses, which means divorcing from technology in certain instances. We’re car people; we build cars for people who love cars. For more information, please visit nilu27.com Contact Details Greg Emmerson, The ID Agency greg@theidagency.com Company Website https://www.nilu27.com/

August 07, 2024 05:55 AM Pacific Daylight Time

Image

Alzamend Neuro Partners with Massachusetts General Hospital for Phase II Trial of AL001 involving Patients with Bipolar Disorder and Alzheimer's Disease

MarketJar

Mental health issues are on the rise, affecting almost 60 million US adults and more than 970 million people worldwide. 1 Rising cases has led to an uptick in new treatments moving through the clinical stages, including Alzamend Neuro, Inc. (NASDAQ:ALZN), which is focused on developing next-generation treatments for Alzheimer’s disease, bipolar disorder (BD), major depressive disorder (MDD), and post-traumatic stress disorder (PTSD). Among its promising pipeline, AL001 stands out as a potential game-changer for bipolar disorder treatment. Alzamend Neuro 's AL001, a patented ionic cocrystal technology, aims to deliver lithium in a way that reduces toxicity while maintaining therapeutic efficacy by combining lithium, salicylate, and L-proline. Alzamend Neuro is rapidly advancing treatments for mental health disorders, potentially accelerating clinical phase progress due to the successes of AL001 in a Phase I and Phase IIA clinical trials for the treatment of Alzheimer’s. In 2023, the company filed IND applications for Phase IIA Clinical Trials of AL001 for Bipolar Disorder, MDD and PTSD. By the end of 2023, the FDA granted approval for these studies via “Study may proceed” letters. Alzamend Neuro Partners with MGH for Phase II Trial of Next-Generation Lithium Therapeutic Drug Candidate for Bipolar Disorder On August 6th, Alzamend Neuro, Inc. (NASDAQ:ALZN) announced a partnership with Massachusetts General Hospital (MGH) to conduct a Phase II clinical trial of AL001 for treatment of patients with bipolar disorder. MGH, the primary clinical education and research facility of Harvard Medical School, is the world's largest hospital-based research program. Dr. Ovidiu Andronesi MD, PhD, Associate Professor of Radiology at Harvard University and Director of Multinuclear Metabolic Imaging at the Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, will lead the study as the Principal Investigator. The trial will compare AL001 to a marketed lithium carbonate product, focusing on bioavailability and brain distribution of lithium, with the goal of establishing AL001's safe, effective, and tolerable dosing requirements. AL001 is designed to offer the therapeutic benefits of traditional lithium salts while minimizing their toxic side effects. This head-to-head study will measure lithium levels in the brain and structures of bipolar disorder patients, building on mouse studies that suggest AL001 can achieve therapeutic benefits at lower doses. The study will also leverage brain imaging to predict the efficacy and safety of AL001 compared to existing lithium treatments. Alzamend Neuro 's previous Phase IIA studies of AL001 in Alzheimer's patients and healthy subjects have demonstrated a benign safety profile, identifying a candidate dose unlikely to require therapeutic drug monitoring (TDM). This is a significant advancement, as current lithium treatments require rigorous monitoring due to their narrow therapeutic window and potential toxicity. “We are elated to partner with Massachusetts General Hospital and Dr. Andronesi in this pivotal study for our lead therapeutic candidate AL001,” said Alzamend Neuro, Inc. (NASDAQ:ALZN) CEO Stephan Jackman, “If we can develop a next-generation lithium product (AL001) with an improved safety profile and enhanced biodistribution in the brain that would not routinely require therapeutic drug monitoring (TDM), it would constitute a major improvement over current lithium-based treatments and positively impact the 7+ million Americans afflicted with bipolar disorder. We look forward to providing more details regarding study timelines and market opportunity in the near future.” This innovation has the potential to positively impact the over 7 million Americans living with bipolar disorder. Further details about the study timelines and market potential will be shared soon. Alzamend Neuro to Conduct a Phase II Clinical Trial of AL001, involving Patients with Alzheimer’s Disease Alzamend Neuro, Inc. (NASDAQ:ALZN) also just announced a collaboration with Massachusetts General Hospital (MGH) to conduct A Phase II clinical trial for AL001, for the potential treatment of Alzheimer's disease. This trial will involve both Alzheimer’s patients and healthy subjects to compare the bioavailability and brain distribution of AL001 versus a marketed lithium carbonate product. The trial, which will also be led by Dr. Ovidiu Andronesi of Harvard University, aim to establish AL001's safe, effective, and tolerable dosing requirements. The potential to avoid the need for therapeutic drug monitoring (TDM) is also significant, as it could simplify treatment regimens and improve patient compliance. By potentially offering a safer and more effective alternative to traditional lithium treatments, AL001 could revolutionize how Alzheimer's disease is managed. The ability to measure lithium levels directly in the brain and brain structures using advanced imaging techniques will provide invaluable insights into the drug’s efficacy and safety. This approach not only enhances our understanding of how AL001 works but also supports its potential approval through a Section 505(b)(2) pathway with the FDA. If successful, the trial could pave the way for a new era in Alzheimer's treatment, providing hope for millions of patients and their families. Financial Support for Clinical Trial In addition to this groundbreaking partnership, Alzamend Neuro, Inc. (NASDAQ:ALZN) recently secured the first two tranches of a $25 million Series A purchasing agreement. This investment supports the advancement of Alzamend 's clinical trial and the development of next-generation treatments for Alzheimer’s, bipolar disorder, MDD, and PTSD. CEO Stephan Jackman emphasized the company's dedication to advancing clinical milestones and revolutionizing lithium-based therapies for millions affected by these conditions. Click here for more information about Alzamend Neuro, Inc. (NASDAQ:ALZN). [1] https://www.who.int/health-topics/mental-health#tab=tab_2 Disclaimer 1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector. 2) The Article was issued on behalf of and sponsored by, Alzamend Neuro, Inc. Market Jar Media Inc. was paid $1,500 for the production and publishing of this article by Alzamend Neuro, Inc.’s Digital Marketing Agency of Record (Native Ads Inc.). Additional details relating to Market Jar Media Inc.’s engagement by Alzamend Neuro, Inc.’s Digital Marketing Agency of Record (Native Ads Inc.) are set out in https://pressreach.com/disclaimer-alzn. 3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy. 4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on pressreach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on pressreach.com. 5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article. 6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management's expectations regarding Alzamend Neuro, Inc.’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Alzamend Neuro, Inc.’s industry; (b) market opportunity; (c) Alzamend Neuro, Inc.’s business plans and strategies; (d) services that Alzamend Neuro, Inc. intends to offer; (e) Alzamend Neuro, Inc.’s milestone projections and targets; (f) Alzamend Neuro, Inc.’s expectations regarding receipt of approval for regulatory applications; (g) Alzamend Neuro, Inc.’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Alzamend Neuro, Inc.’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Alzamend Neuro, Inc.’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Alzamend Neuro, Inc.’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Alzamend Neuro, Inc.’s ability to enter into contractual arrangements with additional parties; (e) the accuracy of budgeted costs and expenditures; (f) Alzamend Neuro, Inc.’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Alzamend Neuro, Inc. to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Alzamend Neuro, Inc.’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Alzamend Neuro, Inc.’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Alzamend Neuro, Inc.’s business operations (e) Alzamend Neuro, Inc. may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, Alzamend Neuro, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Alzamend Neuro, Inc. nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Alzamend Neuro, Inc. nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document. 7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Alzamend Neuro, Inc. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Alzamend Neuro, Inc. or such entities and are not necessarily indicative of future performance of Alzamend Neuro, Inc. or such entities. 8) Investing is risky. The information provided in this article should not be considered as a substitute for professional financial consultation. Users should be aware that investing in any form carries inherent risks, and as such, there is a possibility of losing some or all of their investment. The value of investments can fluctuate significantly within a short period, and investors must understand that past performance is not indicative of future results. Additionally, users should exercise caution as transactions involving investments may be irreversible, even in cases of fraud or accidental actions. It is crucial to acknowledge that rapidly evolving laws and technical issues can have adverse effects on the usability, transferability, exchangeability, and value of investments. Furthermore, users must be cognizant of potential security risks associated with their investment activities. Individuals are strongly encouraged to conduct thorough research, seek professional advice, and carefully evaluate their risk tolerance before engaging in any investment endeavors. Market Jar Media Inc. is neither an investment adviser nor a broker-dealer. The information presented on the website is provided for informative purposes only and is not to be treated as a recommendation to make any specific investment. No such information on pressreach.com constitutes advice or a recommendation. Contact Details James Young +1 800-340-9767 campaigns@pressreach.com Company Website https://pressreach.com

August 06, 2024 11:45 AM Eastern Daylight Time

Image

Headline

MarketJar

Mental health issues are on the rise, affecting almost 60 million US adults and more than 970 million people worldwide. 1 Rising cases has led to an uptick in new treatments moving through the clinical stages, including Alzamend Neuro, Inc. (NASDAQ:ALZN), which is focused on developing next-generation treatments for Alzheimer’s disease, bipolar disorder (BD), major depressive disorder (MDD), and post-traumatic stress disorder (PTSD). Among its promising pipeline, AL001 stands out as a potential game-changer for bipolar disorder treatment. Alzamend Neuro 's AL001, a patented ionic cocrystal technology, aims to deliver lithium in a way that reduces toxicity while maintaining therapeutic efficacy by combining lithium, salicylate, and L-proline. Alzamend Neuro is rapidly advancing treatments for mental health disorders, potentially accelerating clinical phase progress due to the successes of AL001 in a Phase I and Phase IIA clinical trials for the treatment of Alzheimer’s. In 2023, the company filed IND applications for Phase IIA Clinical Trials of AL001 for Bipolar Disorder, MDD and PTSD. By the end of 2023, the FDA granted approval for these studies via “Study may proceed” letters. Alzamend Neuro Partners with MGH for Phase II Trial of Next-Generation Lithium Therapeutic Drug Candidate for Bipolar Disorder On August 6th, Alzamend Neuro, Inc. (NASDAQ:ALZN) announced a partnership with Massachusetts General Hospital (MGH) to conduct a Phase II clinical trial of AL001 for treatment of patients with bipolar disorder. MGH, the primary clinical education and research facility of Harvard Medical School, is the world's largest hospital-based research program. Dr. Ovidiu Andronesi MD, PhD, Associate Professor of Radiology at Harvard University and Director of Multinuclear Metabolic Imaging at the Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, will lead the study as the Principal Investigator. The trial will compare AL001 to a marketed lithium carbonate product, focusing on bioavailability and brain distribution of lithium, with the goal of establishing AL001's safe, effective, and tolerable dosing requirements. AL001 is designed to offer the therapeutic benefits of traditional lithium salts while minimizing their toxic side effects. This head-to-head study will measure lithium levels in the brain and structures of bipolar disorder patients, building on mouse studies that suggest AL001 can achieve therapeutic benefits at lower doses. The study will also leverage brain imaging to predict the efficacy and safety of AL001 compared to existing lithium treatments. Alzamend Neuro 's previous Phase IIA studies of AL001 in Alzheimer's patients and healthy subjects have demonstrated a benign safety profile, identifying a candidate dose unlikely to require therapeutic drug monitoring (TDM). This is a significant advancement, as current lithium treatments require rigorous monitoring due to their narrow therapeutic window and potential toxicity. “We are elated to partner with Massachusetts General Hospital and Dr. Andronesi in this pivotal study for our lead therapeutic candidate AL001,” said Alzamend Neuro, Inc. (NASDAQ:ALZN) CEO Stephan Jackman, “If we can develop a next-generation lithium product (AL001) with an improved safety profile and enhanced biodistribution in the brain that would not routinely require therapeutic drug monitoring (TDM), it would constitute a major improvement over current lithium-based treatments and positively impact the 7+ million Americans afflicted with bipolar disorder. We look forward to providing more details regarding study timelines and market opportunity in the near future.” This innovation has the potential to positively impact the over 7 million Americans living with bipolar disorder. Further details about the study timelines and market potential will be shared soon. Alzamend Neuro to Conduct a Phase II Clinical Trial of AL001, involving Patients with Alzheimer’s Disease Alzamend Neuro, Inc. (NASDAQ:ALZN) also just announced a collaboration with Massachusetts General Hospital (MGH) to conduct A Phase II clinical trial for AL001, for the potential treatment of Alzheimer's disease. This trial will involve both Alzheimer’s patients and healthy subjects to compare the bioavailability and brain distribution of AL001 versus a marketed lithium carbonate product. The trial, which will also be led by Dr. Ovidiu Andronesi of Harvard University, aim to establish AL001's safe, effective, and tolerable dosing requirements. The potential to avoid the need for therapeutic drug monitoring (TDM) is also significant, as it could simplify treatment regimens and improve patient compliance. By potentially offering a safer and more effective alternative to traditional lithium treatments, AL001 could revolutionize how Alzheimer's disease is managed. The ability to measure lithium levels directly in the brain and brain structures using advanced imaging techniques will provide invaluable insights into the drug’s efficacy and safety. This approach not only enhances our understanding of how AL001 works but also supports its potential approval through a Section 505(b)(2) pathway with the FDA. If successful, the trial could pave the way for a new era in Alzheimer's treatment, providing hope for millions of patients and their families. Financial Support for Clinical Trial In addition to this groundbreaking partnership, Alzamend Neuro, Inc. (NASDAQ:ALZN) recently secured the first two tranches of a $25 million Series A purchasing agreement. This investment supports the advancement of Alzamend 's clinical trial and the development of next-generation treatments for Alzheimer’s, bipolar disorder, MDD, and PTSD. CEO Stephan Jackman emphasized the company's dedication to advancing clinical milestones and revolutionizing lithium-based therapies for millions affected by these conditions. Click here for more information about Alzamend Neuro, Inc. (NASDAQ:ALZN). [1] https://www.who.int/health-topics/mental-health#tab=tab_2 Disclaimer 1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector. 2) The Article was issued on behalf of and sponsored by, Alzamend Neuro, Inc. Market Jar Media Inc. was paid $1,500 for the production and publishing of this article by Alzamend Neuro, Inc.’s Digital Marketing Agency of Record (Native Ads Inc.). Additional details relating to Market Jar Media Inc.’s engagement by Alzamend Neuro, Inc.’s Digital Marketing Agency of Record (Native Ads Inc.) are set out in https://pressreach.com/disclaimer-alzn. 3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy. 4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on pressreach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on pressreach.com. 5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article. 6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management's expectations regarding Alzamend Neuro, Inc.’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Alzamend Neuro, Inc.’s industry; (b) market opportunity; (c) Alzamend Neuro, Inc.’s business plans and strategies; (d) services that Alzamend Neuro, Inc. intends to offer; (e) Alzamend Neuro, Inc.’s milestone projections and targets; (f) Alzamend Neuro, Inc.’s expectations regarding receipt of approval for regulatory applications; (g) Alzamend Neuro, Inc.’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Alzamend Neuro, Inc.’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Alzamend Neuro, Inc.’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Alzamend Neuro, Inc.’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Alzamend Neuro, Inc.’s ability to enter into contractual arrangements with additional parties; (e) the accuracy of budgeted costs and expenditures; (f) Alzamend Neuro, Inc.’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Alzamend Neuro, Inc. to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Alzamend Neuro, Inc.’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Alzamend Neuro, Inc.’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Alzamend Neuro, Inc.’s business operations (e) Alzamend Neuro, Inc. may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, Alzamend Neuro, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Alzamend Neuro, Inc. nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Alzamend Neuro, Inc. nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document. 7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Alzamend Neuro, Inc. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Alzamend Neuro, Inc. or such entities and are not necessarily indicative of future performance of Alzamend Neuro, Inc. or such entities. 8) Investing is risky. The information provided in this article should not be considered as a substitute for professional financial consultation. Users should be aware that investing in any form carries inherent risks, and as such, there is a possibility of losing some or all of their investment. The value of investments can fluctuate significantly within a short period, and investors must understand that past performance is not indicative of future results. Additionally, users should exercise caution as transactions involving investments may be irreversible, even in cases of fraud or accidental actions. It is crucial to acknowledge that rapidly evolving laws and technical issues can have adverse effects on the usability, transferability, exchangeability, and value of investments. Furthermore, users must be cognizant of potential security risks associated with their investment activities. Individuals are strongly encouraged to conduct thorough research, seek professional advice, and carefully evaluate their risk tolerance before engaging in any investment endeavors. Market Jar Media Inc. is neither an investment adviser nor a broker-dealer. The information presented on the website is provided for informative purposes only and is not to be treated as a recommendation to make any specific investment. No such information on pressreach.com constitutes advice or a recommendation. Contact Details James Young +1 800-340-9767 campaigns@pressreach.com Company Website https://pressreach.com

August 06, 2024 09:00 AM Eastern Daylight Time

Image

THE ANNUAL BELLAMI SHOWCASE RETURNS SEPTEMBER IN VEGAS

BELLAMI

BELLAMI is thrilled to announce the return of The BELLAMI Showcase in Las Vegas September 29 th to October 1 st 2024. This one-of-a-kind event brings hair stylists and extension artists from around the world together to experience creative inspiration and cutting-edge education. BELLAMI will also honor standout stylists through THE BELLAMIs, the hair extension industry’s only awards for artistic and technical merit. “We are excited to bring back an event that celebrates the artistry and innovation within the hair extensions industry. It is a unique platform for stylists and extension artists to connect and learn from each other,” says BELLAMI President Mary Burns. “We are the only extension company to host an event this large and this year’s showcase will be the first glimpse into our diverse range of Advanced Education offerings for 2025 and provide a sneak peek into several new innovations including a collection that will expand our offerings to a broader, more inclusive audience.” The three-day event takes place at The Palms Hotel, Las Vegas, and encompasses informative mainstage presentations, business panels, advanced hands-on classes and networking events including a celebratory party. Event presenters and educators are some of BELLAMI’s most distinguished high profile stylist partners: Hair Extension Master & Business Mogul Eric Vaughn, Luxury Bridal Hair Expert Senada Ceka, Viral-Haircutting Authority Justin Toves-Vincilione, Mega Celebrity Stylist, Andrew Fitzsimons, Certified Financial Educator and Beauty Finance Group Founder, Anna Manukyan and Blonding Specialist, Sabrina Bias. Color artist & expert in curating engaging content Carlos Rojas will serve as Master of Ceremony. Jessica Iozzo and Caitlin Meehan will join the business panel to share their experience building successful businesses out of hair extensions. The dynamic mainstage presentations and business panels, accessible to all General Admission and VIP guests, will encompass stimulating visuals on cutting edge styling techniques, recounts of the personal journeys from some of our most successful partners, and illuminating discussions on trending topics within the extension business industry. The advanced ‘Look & Learn’ classes will take a deeper dive into these subjects and are available with an additional ticket purchase. Guests can purchase bundled packages to attend up to three courses at a discounted rate. The ‘Look & Learn’ classes serve as a pilot program for a comprehensive educational series in 2025 and provide real-time feedback on what BELLAMI’s audience is most excited about. This initiative re-engages over 20,000 stylists who have already participated in past BELLAMI Master Classes while attracting a broader audience of extensionists eager to enhance their skills and delve into specific niches within the extensions industry. Classes include: In-Depth Education: Stylists will have the opportunity to delve deeper into Main Stage presentations, advancing education with up to three exclusive extension-focused courses in a single day. Personal Interaction with Industry Leaders: Attendees will enjoy an intimate setting with a maximum of 100-200 participants, a stark contrast to the Main Stage Showcase's 1,000+ audience. This allows up-close and personal interactions with industry leaders who inspire their community on social media. Exclusive Preview: Participants will get a first look at new educational content that may be added to the Bellami Academy Advanced Education curriculum in 2025. This might be the only chance to experience these courses taught by the masterminds themselves - an opportunity not to be missed. Topics incorporate: Mastering Extension Methods with Eric Vaughn Using Eric’s exclusive professional collection of K-Tip, Flex Weft, and Tape-In extensions, he will showcase his expert techniques in seamlessly mixing shades to achieve flawless blends and transitions. Focusing on precision and innovation, Eric shares insights from years of experience as a distinguished salon owner and hair stylist. This class will offer a first look at some of BELLAMI’s top secret launches. Bridal Hair & Ultimate Bridal Styling with Senada Ceka Known for her breathtaking bridal looks, Senada Ceka showcases how to achieve wedding styles of the elite and famous using BELLAMI Silk Seam Clip-in Hair Extensions. This is a rare opportunity to witness the mastery behind her famous Hollywood waves and her unique ability to infuse modern flair in any style. Cutting Techniques with Justin Toves-Vincilion e Enter the world of flawless haircutting with Justin, one of the industry's most respected and sought-after hairstylists. With his renowned expertise in creating undetectable seamless blends, Justin reveals his unparallelled artistry as he unleashes the innerworkings of some of his greatest cutting masterpieces. Class-goers will leave with an elevated skill set to deliver 100% guaranteed client satisfaction. Iconic Styling with Dhairius Thomas and Kendall Dorsey Catch a glimpse into the thrilling life of being a set-stylist to celebrities like Rihanna & Kehlani. These two celebrity stylists share their secrets on how to think on your toes in a fast-paced environment and how to use your long-time fan-favorite products BELLAMI Silk Seam Clip-In Extensions and the latest BELLAMI innovation, "The Ponytail" by BELLAMI x Andrew Fitzsimons. THE BELLAMIs Awards will take place on Monday, September 30 th, 2024, announcing winners across eight categories: Best Transformation Before/After Photo, Best Transformation 1-min Video, Best Under-The-Hood, Best Cut 10-sec Video, Best Editorial Look, Best Bridal Look, Most Innovative Technique, and BELLAMI’s Choice. Winners earn a cash prize of $3,000 each and are celebrated on BELLAMI’s social media channels, email distribution, and Bellamiprofessional.com. THE BELLAMIs are open to all BELLAMI independent stylists, salon owners and educators. The BELLAMI Showcase and class tickets are available for $149 (Early Bird), $199 (General Admission), $399 (VIP), and $299/Class. Individual and salon bundles are available ranging from $699 to $1,399. For tickets to The BELLAMI Showcase, visit Bellami Awards - BELLAMI PROFESSIONAL. ABOUT BELLAMI Founded in 2012, BELLAMI is the #1 hair extension brand in the world with the broadest color assortment in the industry. With complete control over their ethical sourcing, manufacturing and quality processes, BELLAMI ensures sustainability and high-performance with its range of luxurious, full-cuticle 100% Human Remy hair extensions. BELLAMI's products for consumers and salon professionals include clip-in extensions and the four pro hair extension methods - sew-in wefts, tape-ins, keratin tips, i-tips. BELLAMI products are available at BELLAMIHair.com and BELLAMI Beauty Bars across the US. BELLAMI is headquartered in Los Angeles, California. ABOUT BEAUTY INDUSTRY GROUP Established in 2004, Beauty Industry Group is an industry leader for professionally installed and DIY hair extensions and related beauty products. Beauty Industry Group's professional products are sold in more than 1,200 stores throughout North America and its collective brands service more than 30,000 salons across over 165 countries. Beauty Industry Group has offices in 6 countries and is headquartered in Salt Lake City, UT. Contact Details Linsey Tilbor Rubin +1 732-991-5294 ltilbor@rellmc.com Katharine Pape +1 917-515-6165 kathy@papepr.com Company Website https://www.bellamihair.com/

August 06, 2024 08:43 AM Eastern Daylight Time

Image

New Book by Denise Edwards, "On the Call, On the Wall," Available Now

On The Call On The Wall

Denise Edwards, a renowned International Prayer Leader and Intercessor, is set to release her inspiring new book, "On the Call, On the Wall," on August 1st. This compelling publication offers readers an in-depth look into the power of prayer, faith, and divine calling through Denise’s personal experiences and spiritual insights. About the Book: "On the Call, On the Wall" is an exploration of Denise Edwards’ journey as an apostolic intercessor and prayer leader. The book delves into her profound experiences with spiritual warfare, intercessory prayer, and her steadfast commitment to the Great Commission. It is filled with powerful narratives that highlight the impact of a life dedicated to prayer and service. What to Expect: Readers can expect to find heartfelt stories, teachings, and testimonies that reveal the challenges and victories of a life led by faith. The book is designed to encourage and empower individuals to deepen their own spiritual practices and to understand the significant role of intercessory prayer in the Christian faith. Availability: "On the Call, On the Wall" will be available for purchase now on Amazon.com and directly through the official website, www.onthecallonthewall.com. From the Author: "I am thrilled to share 'On the Call, On the Wall' with you all," said Denise Edwards. "This book is a culmination of many years of ministry and prayer, and I hope that it will inspire readers to embrace the power of prayer and to recognize the profound impact it can have on their lives and the lives of others." Order your copy today at www.onthecallonthewall.com Media Contacts: www.GCUPUBLISHING.com www.Pubcowire.com https://theronedwards.com About Denise Edwards: Denise Edwards is an International Prayer Leader, Apostolic Intercessor, Seer, Senior Chaplain, Instructor, Speaker, and Shofar Minister. She is the founder of C.O.M.E. Ministries and has dedicated her life to teaching and leading others in the powerful ministry of prayer. Join us as we celebrate the launch of "On the Call, On the Wall" — a must-read for anyone interested in the transformative power of prayer and the impact of living a faith-filled life. For more information about "On the Call, On the Wall" and to schedule interviews or speaking engagements with Denise Edwards, please visit onthecallonthewall.com or contact team@onthecallonthewall.com / media@gcupublishing.com Contact Details GCU Publishing (.com) William Hodge +1 888-428-0095 media@gcupublishing.com

August 02, 2024 02:06 PM Eastern Daylight Time

Image

Overview of Consumer Staples Select Sector SPDR Fund (XLP) Portfolio Composition

Select Sector SPDR

The Consumer Staples Select Sector SPDR Fund (XLP) continues to emphasize its investment focus within the consumer staples sector. Made up of stocks within the S&P 500, XLP offers investors exposure to companies involved in the provision of essential goods and services. The fund is structured around industries that traditionally show resilience, by focusing on everyday essentials. Highlighted Holdings* in XLP's Portfolio: Procter & Gamble (14.72%): A well-known multinational corporation with a diverse product line in personal health/consumer health, and personal care/hygiene. Costco Wholesale (14.25%): A global chain known for its membership warehouses, offering a broad selection of merchandise. Walmart (10.94%): The largest retailer globally, offering a wide range of products at discounted prices. Coca-Cola (9.33%): Recognized as the largest beverage company globally, Coca-Cola operates in more than 200 countries. PepsiCo (4.52%): Offers a variety of beverages and snack foods recognized worldwide. Philip Morris Int’l (4.45%): Engaged in the manufacture and sale of cigarettes and other nicotine-containing products. Mondelez (3.83%): Specializes in chocolate, biscuits, gum, candy, coffee, and powdered beverages. Colgate-Palmolive (3.47%): Focuses on oral care, personal care, home care, and pet nutrition products. Altria (3.41%): Known for producing tobacco, cigarettes, and related products. Target (2.99%): A retailer that provides a diverse assortment of goods. Investment Focus on Essential Goods and Services: The composition of XLP's portfolio underscores its commitment to industries anticipated to maintain steady demand irrespective of economic conditions. This approach is reflective of a strategy aiming to provide investors with exposure to segments of the market where consumer demand persists. With assets totaling over $15 billion, XLP represents a notable presence in the ETF landscape since its inception in 1998. It offers an expense ratio of 0.09%**, positioning itself as a fund that focuses on large-cap companies within the consumer staples sector. About Consumer Staples Select Sector SPDR Fund (XLP): XLP is part of the Select Sector SPDR suite, which targets specific sectors of the S&P 500. By concentrating on companies that produce and distribute essential goods and services, XLP aims to offer a reflection of the consumer staples sector. DISCLAIMER: This is a work of research and should not be taken as investment or financial advice. Therefore, Select Sector SPDRs or the publisher is not liable for any decision made based on the publication. About the Company: Select Sector SPDR ETFs offer flexibility and customization opportunities. Many investors have similar outlooks, but no two are exactly alike. Select Sector SPDR ETFs let investors select the sectors that best meet their investment goals. *Holdings, Weightings & Assets as of 6/30/24 subject to change **Ordinary brokerage fees apply DISCLOSURES The S&P 500 Index is an unmanaged index of 500 common stocks that is generally considered representative of the U.S. stock market. The index is heavily weighted toward stocks with large market capitalizations and represents approximately two-thirds of the total market value of all domestic common stocks. The S&P 500 Index figures do not reflect any fees, expenses or taxes. An investor should consider investment objectives, risks, fees and expenses before investing. One may not invest directly in an index. Transparent ETFs provide daily disclosure of portfolio holdings and weightings All ETFs are subject to risk, including loss of principal. Sector ETF products are also subject to sector risk and nondiversification risk, which generally will result in greater price fluctuations than the overall market. Diversification does not eliminate risk. An investor should consider investment objectives, risks, charges and expenses carefully before investing. To obtain a prospectus, which contains this and other information, call 1-866-SECTOR-ETF (732-8673) or visit www.sectorspdrs.com. Read the prospectus carefully before investing. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is distributor for the Select Sector SPDR Trust. Media Contact: Company: Select Sector SPDRs Contact: Dan Dolan* Address: 1290 Broadway, Suite 1000, Denver, CO 80203 Country: United States Email: dan.dolan@sectorspdrs.com Website: https://www.sectorspdrs.com/ *Dan Dolan is a Registered Representative of ALPS Portfolio Solutions Distributor, Inc. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is the distributor for the Select Sector SPDR Trust. SEL007683 EXP 9/30/24 Contact Details Dan Dolan +1 203-935-8103 dan.dolan@sectorspdrs.com Company Website https://www.sectorspdrs.com/

August 02, 2024 05:00 AM Eastern Daylight Time

What’s Cool for School 2024

News Media Group, Inc.

Contact Details Karl Wayne +1 334-440-6397 karl@newsmg.com Company Website https://newsmg.com/

August 01, 2024 01:10 PM Eastern Daylight Time

Video

Mothers' Milk Bank California Launches Cares Program and Marks 50 Years of Service

The Mothers' Milk Bank

Mothers' Milk Bank California (MMB California), the oldest continuously operating independent nonprofit milk bank in the United States, celebrates a significant milestone of half a century dedicated to serving infants and families in need across the country. MMB has updated the name of the organization to include 'California' to honor its roots in the state. Central to MMB California's legacy is a network of more than 30 nonprofit mothers’ milk banks across the United States and in Mexico that have followed the model MMB California established 50 years ago. Since 1974, Mothers’ Milk Bank California has distributed 16 million ounces of human donor milk to some of the country’s most at-risk babies. That’s equivalent to filling 7 swimming pools with liquid gold. Our community of milk donors at MMB California is nearly 25,000 strong, supporting thousands of families in their times of need. The organization collaborates with a growing number of hospitals nationwide to provide safe, lifesaving nourishment to their tiniest patients. MMB California advances the milk banking industry through partnerships, research support, and advocacy for stringent health and safety guidelines. “As we celebrate our 50th anniversary, we reflect on the incredible journey of saving lives and supporting families. Our new MMB California Cares Program is a testament to our commitment to quality, efficiency, equity, and education. We are excited to continue our mission and expand our reach to ensure that every baby in need has access to safe donor milk,” said Jennifer Benito-Kowalski, Chief Executive Officer of Mothers' Milk Bank California. Today, MMB California announced the launch of their 50th anniversary, MMB California Cares Program, along with their vision for the next 50 years. This initiative aims to build and strengthen the Milk Donor Community, highlighting the ongoing dedication to: Quality Assurance and Compliance: Upholding rigorous standards for processing and distributing donor human milk to ensure safety and efficacy. Efficiency and Excellence: Streamlining operations to maximize the impact of milk donations across our expanding network. Equity and Access Initiatives: Increasing access to donor human milk for all families in California and beyond. Education and Outreach Campaigns: Launching comprehensive programs to raise awareness about the life-saving benefits of donor human milk and foster community among donors and recipients. Alongside these initiatives, Mothers' Milk Bank California has unveiled a newly redesigned website. Featuring enhanced navigation and user-friendly interfaces, the site provides resources for donors, healthcare providers, and families seeking support. About Mothers’ Milk Bank California Founded 50 years ago, Mothers’ Milk Bank California is a leading nonprofit dedicated to providing screened, donated human milk to babies in need. As a founding member of the Human Milk Banking Association of North America (HMBANA), it helped set standards for nonprofit milk banks across North America. The organization collects, pasteurizes, and distributes safe human milk to hospitals and families, ensuring essential nutrition for infants. Committed to improving lives, Mothers’ Milk Bank California supports families and advances neonatal care. For more information about Mothers' Milk Bank California, our initiatives, and to explore our new website, please visit MothersMilk.org. For media inquiries, contact: Angelica Rojas at D: (877) 375-6645 ext. 4 | E: angelica.rojas@MothersMilk.org Founded 50 years ago, Mothers' Milk Bank California is a leading nonprofit dedicated to providing screened, donated human milk to babies in need. As a founding member of the Human Milk Banking Association of North America (HMBANA), it helped set standards for nonprofit milk banks across North America. The organization collects, pasteurizes, and distributes safe human milk to hospitals and families, ensuring essential nutrition for infants. Committed to improving lives, Mothers' Milk Bank California supports families and advances neonatal care. Contact Details Mothers' Milk Bank California Jennifer Benito-Kowalski +1 408-831-7276 jbenito@mothersmilk.org Company Website https://camilkbank.org/

August 01, 2024 08:03 AM Pacific Daylight Time

AmeriLife Welcomes Elite Insurance Group to Its Rapidly Expanding Health Distribution Network

AmeriLife

AmeriLife Group, LLC (“AmeriLife”), a national leader in developing, marketing, and distributing life and health insurance, annuities, and retirement planning solutions, announced today that it has partnered with Elite Insurance Group, an independent, Reidsville, Georgia-based insurance brokerage that specializes in the Medicare, health insurance, and life insurance markets. Per the agreement, terms of the deal were not disclosed. “We are so happy to become part of the AmeriLife family,” said David Wilson, owner and Chief Executive Officer of Elite Insurance Group. “This partnership will allow us to take our business to the next level and ensure the continued success of our company.” “This partnership gives us and our employees the opportunity to provide outstanding resources and benefits that our clients deserve,” added Hunter Davis, Chief Operating Officer of Elite Insurance Group. “We look forward to expanding the excellence of the Elite Insurance Group brand with our new partners.” Elite Insurance Group, which is licensed in 28 states and has satellite offices in Alabama, Virginia, and Kentucky, has been serving the senior market since 2005, by simplifying the health and life insurance buying process for clients – all with a personal touch. As a full-service brokerage founded on the values of honesty, integrity, and trust, the company offers deep and diverse plan options from some of the industry’s top carriers to ensure its clients find the best benefits and savings for themselves and their families. As Elite Insurance Group joins AmeriLife’s growing Health Distribution organization, it will enjoy access to a number of best-in-class platforms, tools, and resources that will help accelerate its already impressive growth and serve more beneficiaries. “I’m thrilled to welcome David, Hunter, and their ‘Elite’ team to AmeriLife,” said Scotty Elliott, Chief Distribution Officer of Health for AmeriLife. “As we continue to navigate disruption and change throughout our industry, it’s important that we bring onboard strong, resilient partners who are built for clients’ needs today and tomorrow, and Elite Insurance Group is exactly that kind of partner. We can’t wait to get to work together.” ### About Elite Insurance Group Since 2005, Elite Insurance Group has been specializing in the senior market. As an independent insurance company, we strive to uphold professional values such as honesty, integrity, and trust. By following these guiding principles, we have become just what our name states: elite. Our mission at Elite Insurance Group is to support and provide our agents with the resources they need to serve the senior market with the appropriate selections of health and life insurance products they and their clients need. To learn more, visit Elite-InsGroup.com. About AmeriLife AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as a leader in developing, marketing, and distributing life and health insurance, annuities and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For more than 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers served through a distribution network of over 300,000 insurance agents and advisors and 120 marketing organizations and insurance agency locations nationwide. For more information, visit AmeriLife.com, and follow AmeriLife on Facebook and LinkedIn. Contact Details Media Jeff Maldonado media@amerilife.com Partnership Inquiries Patrick Nichols corporatedevelopment@amerilife.com Company Website https://amerilife.com/

August 01, 2024 09:00 AM Eastern Daylight Time